# Xenetic Biosciences, Inc.: financial statements, quarterly

XBIO · Nasdaq · CIK 1534525 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xbio.md) · [Financials](/companies/xbio/financials.md) · [Filings](/companies/xbio/filings.md) · [Insiders](/companies/xbio/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xbio/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [611](/filings/0001683168-24-007903.md) | [672 d](/filings/0001683168-25-001686.md) | [511](/filings/0001683168-25-003496.md) | [726](/filings/0001683168-25-005983.md) | [614](/filings/0001683168-25-008259.md) | [649 d](/filings/0001683168-26-001737.md) | [593](/filings/0001683168-26-003727.md) | [590](/filings/0001683168-26-006061.md) | [1,027](/filings/0001683168-25-008259.md) | [766 d](/filings/0001683168-26-001737.md) | [807](/filings/0001683168-26-003727.md) | [661](/filings/0001683168-26-006061.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [1,021](/filings/0001683168-24-007903.md) | [976 d](/filings/0001683168-25-001686.md) | [944](/filings/0001683168-25-003496.md) | [934](/filings/0001683168-25-005983.md) | [368](/filings/0001683168-25-008259.md) | [1,042 d](/filings/0001683168-26-001737.md) | [879](/filings/0001683168-26-003727.md) | [657](/filings/0001683168-26-006061.md) | [756](/filings/0001683168-25-008259.md) | [773 d](/filings/0001683168-26-001737.md) | [661](/filings/0001683168-26-003727.md) | [552](/filings/0001683168-26-006061.md) |
| Operating income | $k | [(1,147)](/filings/0001683168-24-007903.md) | [(1,256) d](/filings/0001683168-25-001686.md) | [(1,268)](/filings/0001683168-25-003496.md) | [(1,337)](/filings/0001683168-25-005983.md) | [(499)](/filings/0001683168-25-008259.md) | [(1,099) d](/filings/0001683168-26-001737.md) | [(942)](/filings/0001683168-26-003727.md) | [(724)](/filings/0001683168-26-006061.md) | [(545)](/filings/0001683168-25-008259.md) | [(623) d](/filings/0001683168-26-001737.md) | [(502)](/filings/0001683168-26-003727.md) | [(972)](/filings/0001683168-26-006061.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [0.0](/filings/0001683168-24-007903.md) | [0.0 d](/filings/0001683168-25-001686.md) | [0.0](/filings/0001683168-25-003496.md) | [0.0](/filings/0001683168-25-005983.md) | [0.0](/filings/0001683168-25-008259.md) | [0.0 d](/filings/0001683168-26-001737.md) | [0.0](/filings/0001683168-26-003727.md) | [0.0](/filings/0001683168-26-006061.md) | [0.0](/filings/0001683168-25-008259.md) | [0.0 d](/filings/0001683168-26-001737.md) | [0.0](/filings/0001683168-26-003727.md) | [0.0](/filings/0001683168-26-006061.md) |
| Net income | $k | [(1,056)](/filings/0001683168-24-007903.md) | [(1,172) d](/filings/0001683168-25-001686.md) | [(1,195)](/filings/0001683168-25-003496.md) | [(1,274)](/filings/0001683168-25-005983.md) | [(437)](/filings/0001683168-25-008259.md) | [(1,055) d](/filings/0001683168-26-001737.md) | [(903)](/filings/0001683168-26-003727.md) | [(689)](/filings/0001683168-26-006061.md) | [(510)](/filings/0001683168-25-008259.md) | [(579) d](/filings/0001683168-26-001737.md) | [(456)](/filings/0001683168-26-003727.md) | [(930)](/filings/0001683168-26-006061.md) |
| Diluted EPS | $ per share | [(0.69)](/filings/0001683168-24-007903.md) | not reported | [(0.78)](/filings/0001683168-25-003496.md) | [(0.83)](/filings/0001683168-25-005983.md) | [(0.28)](/filings/0001683168-25-008259.md) | not reported | [(0.59)](/filings/0001683168-26-003727.md) | [(0.45)](/filings/0001683168-26-006061.md) | [(0.33)](/filings/0001683168-25-008259.md) | not reported | [(0.20)](/filings/0001683168-26-003727.md) | [(0.41)](/filings/0001683168-26-006061.md) |
| Basic EPS | $ per share | [(0.69)](/filings/0001683168-24-007903.md) | not reported | [(0.78)](/filings/0001683168-25-003496.md) | [(0.83)](/filings/0001683168-25-005983.md) | [(0.28)](/filings/0001683168-25-008259.md) | not reported | [(0.59)](/filings/0001683168-26-003727.md) | [(0.45)](/filings/0001683168-26-006061.md) | [(0.33)](/filings/0001683168-25-008259.md) | not reported | [(0.20)](/filings/0001683168-26-003727.md) | [(0.41)](/filings/0001683168-26-006061.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [9.8](/filings/0001683168-23-007820.md) | [9.0](/filings/0001683168-25-001686.md) | [7.8](/filings/0001683168-24-003172.md) | [7.3](/filings/0001683168-24-005572.md) | [6.8](/filings/0001683168-24-007903.md) | [6.2](/filings/0001683168-25-003496.md) | [5.2](/filings/0001683168-25-003496.md) | not reported | not reported | [7.9](/filings/0001683168-26-003727.md) | [7.3](/filings/0001683168-26-003727.md) | not reported |
| Current assets | $m | [11.3](/filings/0001683168-23-007820.md) | [9.6](/filings/0001683168-25-001686.md) | [8.4](/filings/0001683168-24-003172.md) | [8.0](/filings/0001683168-24-005572.md) | [7.0](/filings/0001683168-24-007903.md) | [6.6](/filings/0001683168-26-001737.md) | [5.5](/filings/0001683168-25-003496.md) | [5.4](/filings/0001683168-25-005983.md) | [5.1](/filings/0001683168-25-008259.md) | [8.0](/filings/0001683168-26-006061.md) | [7.6](/filings/0001683168-26-003727.md) | [6.7](/filings/0001683168-26-006061.md) |
| Total assets | $m | [12.0](/filings/0001683168-23-007820.md) | [10.6](/filings/0001683168-25-001686.md) | [9.4](/filings/0001683168-24-003172.md) | [9.0](/filings/0001683168-24-005572.md) | [8.0](/filings/0001683168-24-007903.md) | [6.9](/filings/0001683168-26-001737.md) | [5.8](/filings/0001683168-25-003496.md) | [5.4](/filings/0001683168-25-005983.md) | [5.1](/filings/0001683168-25-008259.md) | [8.4](/filings/0001683168-26-006061.md) | [7.9](/filings/0001683168-26-003727.md) | [7.0](/filings/0001683168-26-006061.md) |
| Current liabilities | $m | [1.1](/filings/0001683168-23-007820.md) | [0.8](/filings/0001683168-25-001686.md) | [0.7](/filings/0001683168-24-003172.md) | [1.6](/filings/0001683168-24-005572.md) | [1.0](/filings/0001683168-24-007903.md) | [0.9](/filings/0001683168-26-001737.md) | [0.7](/filings/0001683168-25-003496.md) | [0.9](/filings/0001683168-25-005983.md) | [1.1](/filings/0001683168-25-008259.md) | [1.0](/filings/0001683168-26-006061.md) | [1.0](/filings/0001683168-26-003727.md) | [0.9](/filings/0001683168-26-006061.md) |
| Total liabilities | $m | [1.1](/filings/0001683168-23-007820.md) | [0.8](/filings/0001683168-25-001686.md) | [0.7](/filings/0001683168-24-003172.md) | [1.6](/filings/0001683168-24-005572.md) | [1.0](/filings/0001683168-24-007903.md) | [0.9](/filings/0001683168-26-001737.md) | [0.7](/filings/0001683168-25-003496.md) | [0.9](/filings/0001683168-25-005983.md) | [1.1](/filings/0001683168-25-008259.md) | [1.0](/filings/0001683168-26-006061.md) | [1.0](/filings/0001683168-26-003727.md) | [0.9](/filings/0001683168-26-006061.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [10.9](/filings/0001683168-24-007903.md) | [9.8](/filings/0001683168-26-001737.md) | [8.7](/filings/0001683168-25-005983.md) | [7.4](/filings/0001683168-25-008259.md) | [7.0](/filings/0001683168-25-008259.md) | [6.0](/filings/0001683168-26-006061.md) | [5.1](/filings/0001683168-26-006061.md) | [4.5](/filings/0001683168-26-006061.md) | [4.0](/filings/0001683168-25-008259.md) | [7.4](/filings/0001683168-26-006061.md) | [7.0](/filings/0001683168-26-006061.md) | [6.1](/filings/0001683168-26-006061.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(950) d](/filings/0001683168-24-007903.md) | [(793) d](/filings/0001683168-25-001686.md) | [(1,159)](/filings/0001683168-25-003496.md) | [(525) d](/filings/0001683168-25-005983.md) | [(459) d](/filings/0001683168-25-008259.md) | [(674) d](/filings/0001683168-26-001737.md) | [(1,002)](/filings/0001683168-26-003727.md) | [(384) d](/filings/0001683168-26-006061.md) | [(658) d](/filings/0001683168-25-008259.md) | [(243) d](/filings/0001683168-26-001737.md) | [(536)](/filings/0001683168-26-003727.md) | [(875) d](/filings/0001683168-26-006061.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [1,432](/filings/0001683168-23-007820.md) | [1,517](/filings/0001683168-24-003172.md) | [1,525](/filings/0001683168-24-005572.md) | [1,533](/filings/0001683168-24-007903.md) | [1,541](/filings/0001683168-25-003496.md) | [1,541](/filings/0001683168-25-005983.md) | [1,542](/filings/0001683168-25-008259.md) | [1,542](/filings/0001683168-26-003727.md) | [1,542](/filings/0001683168-26-006061.md) | [1,542](/filings/0001683168-25-008259.md) | [2,291](/filings/0001683168-26-003727.md) | [2,294](/filings/0001683168-26-006061.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 2,343,181 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001683168-26-006061.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.